Trevi's FDA Alignment Mandates Dual Phase 3 Trials, Validating Bearish Regulatory Risks

What happened

Trevi Therapeutics has completed its End-of-Phase 2 meeting with the FDA, gaining alignment to conduct two Phase 3 clinical trials of nalbuphine ER for IPF-related chronic cough. This directly matches the DeepValue report's bear scenario, where FDA feedback requiring a multi-trial program was flagged as a key downside risk. The move to dual trials contradicts earlier investor hopes for a streamlined single-trial design, which the report noted could have boosted the thesis. Given Trevi's single-asset dependency and already high valuation, this development escalates execution complexity, cost, and timeline delays. Thus, the news underscores the report's cautious stance and potential for capital impairment.

Implication

The requirement for two Phase 3 trials will likely accelerate Trevi's cash burn, compressing its runway into 2028 and raising the probability of another equity raise before pivotal data. Delayed regulatory milestones push potential revenue further out, reducing the net present value of future cash flows and justifying a lower stock price. With crowded bullish sentiment and high institutional ownership, any operational slippage or funding stress could trigger significant sell-offs. Competitors such as GSK's camlipixant may advance in parallel, threatening Haduvio's first-mover advantage and eroding long-term commercial assumptions. Therefore, maintaining or initiating positions at current levels offers unfavorable risk-reward, and investors should prioritize capital preservation by reducing exposure until Phase 3 execution de-risks.

Thesis delta

The news confirms the regulatory headwind identified in the DeepValue report, shifting the probability weight from the base scenario toward the bear scenario. Previously, there was uncertainty around FDA demands, but now with two trials mandated, cost and timeline risks have materialized, increasing the likelihood of dilution and downward stock pressure. This reinforces the sell call and suggests that attractive entry points, if any, are now lower than the previously estimated $8.50.